Testing Apixaban to Prevent Bleeding Complications in Cirrhosis
Treatments studied
Part of Brain & nervous system, Digestive system, Hormones & metabolism clinical trials.
This study tests whether a blood thinner called apixaban can safely prevent dangerous bleeding in people with cirrhosis (liver scarring) who have portal hypertension (high blood pressure in veins leading to the liver). The goal is to see if it reduces bleeding risk without causing excessive bleeding.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older with confirmed cirrhosis (liver scarring from any cause)
- You have portal hypertension, shown by enlarged veins, fluid buildup in your belly, or enlarged spleen
- Your liver disease is stable or mildly worsened (Child-Pugh score 7–10), with no major changes in the last 3 months
- You had an endoscopy (camera down the throat) in the last 6 months, and any high-risk bleeding veins were treated
- You have not had active bleeding from your stomach or esophagus in the last 6 weeks
- You are willing to stop other blood thinners or aspirin before the study starts
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether a blood thinner called apixaban can treat a blood clot in the main vein to the liver (portal vein) that appeared more than a year after spleen surgery in people with cirrhosis. It compares apixaban to a low-dose aspirin to see if one works better with fewer side effects.
This trial tests if apixaban, a blood thinner, is more effective than aspirin at treating blood clots in the portal vein that form more than a year after laparoscopic spleen removal in people with cirrhosis and an enlarged spleen.
This trial tests a new oral blood thinner to prevent another bleeding episode in people with liver cirrhosis who have already had variceal bleeding and also have a clot in the portal vein. The goal is to see if it can safely reduce the risk of rebleeding.
This study tests whether blood thinners (anticoagulants) are safe and effective for people with cirrhosis and a blood clot in the portal vein. It may also include people with liver cancer (HCC).
This trial tests whether a pill (dabigatran) or a daily injection (enoxaparin) is better at preventing new blood clots in the liver vein for people with cirrhosis. Both are blood thinners, and the study wants to see which one is safer and more effective.
This study compares two ways to prevent future bleeding from enlarged veins in the esophagus or stomach in people with liver cirrhosis. One method uses a small tube (called TIPS) to reduce pressure in the liver, and the other combines a banding procedure with medication. The goal is to see which approach works better.
Hear when a new Cirrhosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.